{"abstract": "As Sanofi-Aventis hunkers down for a long battle to buy Genzyme, the specter of a new proxy battle for control of the company will become an increasingly real threat, sources familiar with the situation told Reuters.", "web_url": "https://dealbook.nytimes.com/2010/10/14/sanofi-wields-threat-of-proxy-battle-for-genzyme/", "snippet": "As Sanofi-Aventis hunkers down for a long battle to buy Genzyme, the specter of a new proxy battle for control of the company will become an increasingly real threat, sources familiar with the situation told Reuters.", "lead_paragraph": "As the French drugmker Sanofi-Aventis hunkers down for a long battle to buy Genzyme, a United States biotech, the specter of a new proxy battle for control of the company will become an increasingly real threat, sources familiar with the situation told Reuters.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Sanofi Wields Threat of Proxy Battle for Genzyme", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Genzyme Corp", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Sanofi-Aventis SA", "rank": 2, "major": "N"}], "pub_date": "2010-10-14T08:18:09+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/a9e167ad-c013-535c-87a2-107ddd19a215", "word_count": 105, "uri": "nyt://article/a9e167ad-c013-535c-87a2-107ddd19a215"}